How to Check Earkart IPO Allotment Status?

Earkart Limited is a HealthTech platform specializing in hearing aids and related accessories, offering modern hearing devices including Receiver-In-Canal, Invisible, Behind-The-Ear, In-The-Ear, In-The-Canal, and Completely-In-Canal models, incorporated with operations through network of partners, clinics, and Shop in Shop model across 49 clinics in 22 cities spanning 6 states and 2 Union Territories, while also distributing adjustable foldable walkers and Multi-Sensory Integrated Educational Development materials for physically challenged individuals, operating manufacturing facility in Noida across 4,500 square feet and serving as trusted Government e-Market supplier of hearing aids to ALIMCO under Ministry of Social Justice and Empowerment.

The Earkart IPO came with a total issue size of ₹49.26 crore, comprising a fresh issue of 0.33 crore shares aggregating to ₹44.75 crore and offer for sale of 0.03 crore shares aggregating to ₹4.51 crore. The IPO opened on September 25, 2025, and closed on September 29, 2025. The allotment for the Earkart IPO is expected to be finalized on Tuesday, September 30, 2025. The Earkart IPO share price was fixed at ₹135 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Earkart IPO Allotment Status on Registrar Site

• Visit the Skyline Financial Services Pvt.Ltd. website
• Select "Earkart" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Earkart IPO Allotment Status on BSE

• Navigate to the BSE SME IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Earkart" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Earkart IPO Subscription Status

Earkart IPO received weak investor interest, being subscribed 1.28 times overall. The subscription showed poor confidence with weak retail participation and moderate NII interest. Here is a category-wise breakdown of the subscription as of 5:05:35 PM on September 29, 2025:

• Non-Institutional Investors (NII): 1.63 times.
• Individual Investors: 0.35 times.

Earkart IPO Share Price and Investment Details

The Earkart IPO stock price was fixed at ₹135 per share with a minimum lot size of 1,000 shares. The minimum investment required for retail investors was ₹2,70,000 for 2 lots (2,000 shares). The issue included 1,85,000 shares allocated to market maker raising ₹2.50 crore. Given the weak subscription response of 1.28 times overall, with particularly poor retail participation at 0.35 times and moderate NII interest, the Earkart IPO share price is expected to list with flat to negative premium.

Utilisation of IPO Proceeds

The funds raised through the IPO will be utilised as follows:

• Funding incremental working capital requirements: ₹21.10 crore.
• Capital expenditure for setting up Shop in Shop Business Model and Infrastructure: ₹17.33 crore.
• General corporate purposes: ₹0.63 crore.

Business Overview

Earkart Limited operates with diversified product portfolio in growing HealthTech sector, multi-channel distribution network spanning online, offline, and B2G sales, expanding Shop in Shop franchise model presence, and government recognition as trusted GeM supplier while demonstrating strong financial performance with 35% revenue increase and 125% PAT rise between FY24-FY25, maintaining healthy financial metrics with 34.55% ROE and low debt-equity ratio of 0.26. The company enjoys niche positioning in hearing aids and assistive devices segment, positioned to benefit from India's aging population and healthcare accessibility trends, though the aggressive pricing reflected in high P/E ratio of 26.98 post-issue and extremely weak retail response with poor overall subscription suggest investors should carefully evaluate valuation versus growth prospects in the competitive HealthTech sector before considering investment.